IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.
Investigators at the University of Texas have synthesized new mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and Bruton tyrosine kinase (BTK) dual-target inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
A Juno Therapeutics Inc. patent describes pyrazole-based DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), an enzyme involved in one-carbon metabolism, is significantly overexpressed in cancer cells but shows limited expression in normal tissues, making it a promising target for cancer therapy.
Lila Biologics Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel radioligand therapies for imaging and treatment of solid tumors.
Hangzhou Polymed Biopharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety via a linker reported to be useful for the treatment of cancer.
Congruence Therapeutics Inc. has closed a $32 million financing round to advance its pipeline of small-molecule correctors for diseases of protein misfolding.
Aptevo Therapeutics Inc. has unveiled two new trispecific candidates, APVO-452 for prostate cancer and APVO-451 for solid tumors. Powered by the company’s Adaptir-Flex platform, each trispecific immune cell engager biologic brings together tumor targeting, T-cell activation and immune costimulation in a single molecule.
RSS
